Lanoxicaps

Ventricular Arrhythmia, Congestive Heart Failure, Atrial Fibrillation + 2 more
Treatment
20 Active Studies for Lanoxicaps

What is Lanoxicaps

DigoxinThe Generic name of this drug
Treatment SummaryDigoxin is a medication used to treat atrial fibrillation and heart failure symptoms. It was first approved by the FDA in 1954 and comes from the foxglove plant, which was studied by an English physician and botanist in the 1780s. This plant has been used to make medications since the 1250s, and Digoxin is one of the oldest cardiovascular medications still in use today.
Digoxinis the brand name
image of different drug pills on a surface
Lanoxicaps Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Digoxin
Digoxin
1975
190

Effectiveness

How Lanoxicaps Affects PatientsDigoxin is a medication that can help people with an irregular heartbeat (atrial fibrillation) by increasing the force of their heartbeat and slowing down their heart rate. Studies have shown that taking digoxin can lead to improved exercise capacity and fewer hospitalizations or emergency visits due to heart failure. However, it has a narrow therapeutic window and can cause potentially fatal side effects, such as ventricular fibrillation or complete heart block, in individuals who have pre-existing sinus node disease or AV block and take digoxin.
How Lanoxicaps works in the bodyDigoxin helps the heart work better by decreasing the heart rate and increasing the force of heart muscle contractions. It does this by blocking a protein that regulates the entry and exit of sodium, potassium and calcium into and out of cells. This increases the amount of sodium and calcium in the cells of the heart muscle, making it stronger. Digoxin also stimulates the parasympathetic nervous system, which decreases neurohormonal activity and lowers the heart rate.

When to interrupt dosage

The suggested dose of Lanoxicaps is contingent upon the diagnosed condition, including Chronic Atrial Fibrillation, mild, moderate Heart Failure and Congestive Heart Failure. The dosage fluctuates as per the method of delivery (e.g. Oral or Liquid - Oral) featured in the table beneath.
Condition
Dosage
Administration
Heart failure
0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection - Intramuscular; Intravenous, Capsule
Congestive Heart Failure
0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection - Intramuscular; Intravenous, Capsule
Atrial Fibrillation
0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection - Intramuscular; Intravenous, Capsule
Myocardial contractility
0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection - Intramuscular; Intravenous, Capsule
Ventricular Arrhythmia
0.125 mg, , 0.25 mg, 0.25 mg/mL, 0.05 mg/mL, 0.1875 mg, 0.0025 mg, 0.00125 mg, 0.0625 mg, 0.1 mg/mL, 0.2 mg, 0.1 mg, 0.5 mg/mL
, Oral, Tablet, Tablet - Oral, Intramuscular; Intravenous; Parenteral, Injection, solution, Solution, Solution - Oral, Injection, solution - Intramuscular; Intravenous, Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Liquid - Oral, Injection, Capsule - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Injection, solution - Intramuscular; Intravenous; Parenteral, Injection - Intramuscular; Intravenous, Capsule

Warnings

Lanoxicaps has three contraindications, and therefore should not be utilized while encountering any of the conditions outlined in the following table.Lanoxicaps Contraindications
Condition
Risk Level
Notes
Ventricular Fibrillation
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Digoxin may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Digoxin may interact with Pulse Frequency
There are 20 known major drug interactions with Lanoxicaps.
Common Lanoxicaps Drug Interactions
Drug Name
Risk Level
Description
Hydroxyzine
Major
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Hydroxyzine.
Mobocertinib
Major
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Mobocertinib.
Revefenacin
Major
Digoxin may decrease the excretion rate of Revefenacin which could result in a higher serum level.
Ziprasidone
Major
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Ziprasidone.
Abexinostat
Minor
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Abexinostat.
Lanoxicaps Toxicity & Overdose RiskThe lowest toxic dose of digoxin for women is 100 micrograms per kilogram, and for men is 75 micrograms per kilogram. In rats, the lowest toxic dose is 28270 micrograms per kilogram. Taking too much digoxin can lead to nausea, vomiting, changes in vision, and irregular heartbeats. People who are older, have a lower body weight, or have decreased kidney function and electrolyte imbalances are at higher risk of digoxin toxicity.
image of a doctor in a lab doing drug, clinical research

Lanoxicaps Novel Uses: Which Conditions Have a Clinical Trial Featuring Lanoxicaps?

308 active trials are currently in progress to assess the ability of Lanoxicaps to address Cardiac Arrhythmias, boost Myocardial contractility, and manage Congestive Heart Failure.
Condition
Clinical Trials
Trial Phases
Congestive Heart Failure
186 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Myocardial contractility
0 Actively Recruiting
Atrial Fibrillation
0 Actively Recruiting
Heart failure
0 Actively Recruiting
Ventricular Arrhythmia
7 Actively Recruiting
Not Applicable, Phase 3, Phase 4

Lanoxicaps Reviews: What are patients saying about Lanoxicaps?

5Patient Review
6/7/2009
Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation
I had used this type Lanoxin for years without any problems. They took it off the market and I have since had severe reactions to regular Lanoxin. I want to know if it has been put back on the market and if it is now available.
5Patient Review
7/10/2008
Lanoxicaps for A Type of Fast Heartbeat - Paroxysmal Atrial Tachycardia
I'm extremely disappointed that Glaxo Smith Kline has stopped making this medication. It helped me and I know it's helped other people too. We should have been notified ahead of time so we could have prepared.
5Patient Review
11/23/2009
Lanoxicaps for Chronic Heart Failure
I've taken Lanoxicaps for over a decade and it's been incredibly effective for me. I had to switch to the Lanoxin form of the drug when Lanoxicaps were taken off the market, but I've since had allergic reactions and other bad reactions to the tablet. It's really unfortunate that there are now fewer medical options for patients with serious cardiac diseases.
5Patient Review
6/3/2008
Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation
I was very upset when they took Lanoxicaps off the market.
4.7Patient Review
12/11/2007
Lanoxicaps for Ventricular Rate Control in Atrial Fibrillation
I'm not sure why this product is no longer available, but my doctor switched me to Atenolol.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lanoxicaps

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What's Digoxin used for?

"UK

Digoxin is a medication used to treat irregular heartbeats."

Answered by AI

What's the generic name for Digoxin?

"The oral tablet form of digoxin is available as both a generic drug and a brand-name drug called Lanoxin. An oral solution of digoxin is also available. Digoxin is used to treat atrial fibrillation, mild to moderate heart failure in adults, and heart failure in children."

Answered by AI

What is Lanoxin used for?

"Digoxin is a medication that is used to treat heart failure and certain types of irregular heartbeat. treating heart failure with digoxin can help improve the patient's ability to walk and exercise, as well as the strength of the heart."

Answered by AI

What are the side effects of Digoxin?

"... , Swelling of your liver ...

You may have Covid-19 if you're feeling confused, dizzy or generally unwell. Other symptoms include feeling or being sick (nausea or vomiting) and loss of appetite, diarrhoea, changes in your vision (including blurred vision and not being able to look at bright light), skin rashes, swelling of your liver."

Answered by AI

Clinical Trials for Lanoxicaps

Image of Los Angeles General Medical Center in Los Angeles, United States.

Supportive Management for Heart Failure and Methamphetamine Addiction

18+
All Sexes
Los Angeles, CA
Heart failure (HF) affects over 6 million people in the US and is a major cause of both hospital admissions and death. HF has many causes and contributing factors. One of the most aggressive forms of HF is associated with methamphetamine abuse, which has become its own epidemic in the US over the past twenty years. People who use methamphetamine tend to develop HF at a much younger age, with more severe disease and more serious consequences. A recent analysis using nationwide data, methamphetamine use doubled the risk of death or hospitalizations compared to non-users in patients with HF. Thus, methamphetamine users with HF represent a very high-risk group of patients from a healthcare perspective. HF may be reversible in some patients who use methamphetamine if patients can achieve 1) abstain from further methamphetamine use and 2) consistently take all the medications that can improve HF. These two goals are very difficult to achieve in practice, as the care of both methamphetamine addiction and HF requires specialized medical expertise and intensive regular follow up of patients. In general, achievement of one goal is not possible without the other. Patients who use methamphetamine have poor adherence to medical follow-up and therapies, and abstinence from methamphetamine is difficult to maintain. This is further complicated because the current model of HF care does not incorporate treatment for methamphetamine use. The current study proposes to launch a multidisciplinary clinic that treats both HF and methamphetamine use disorder at the same time. The HF care will be led by a cardiologist while the methamphetamine use treatment will be led by a psychiatric clinical pharmacist trained in addiction medicine. State-of-the-art HF care will include optimization of four pillar HF medications. Methamphetamine use treatment will include counseling and incentivized abstinence known as contingency management (CM). The investigators will manage the patients in the clinic for 6 months total. The investigators are interested in demonstrating that this integrated clinic model will result in improved delivery of care for these patients by reporting the rates of successful abstinence from methamphetamine, improved optimization of the four HF medications, and enhanced patient reported quality of life over the 6 months of follow up. The investigators will also collect data on the costs associated with providing this level of care and estimate a range of potential cost-savings.
Waitlist Available
Has No Placebo
Los Angeles General Medical Center (+1 Sites)Tien Ng, PharmD
Have you considered Lanoxicaps clinical trials? We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.Go to Trials
Image of Cleveland Clinic Avon Hospital in Avon, United States.

Wake and Weigh for Heart Failure

18+
All Sexes
Avon, OH
Ongoing self-care for heart failure is essential to avoid complications and hospitalization. Supportive strategies are needed; however, patients with heart failure may find many interventions complicated and overwhelming. The purpose of this pilot study is to implement a simple weight tracking tool (Wake and Weigh) to affect self-care and quality of life in a population of older adults with heart failure. This will be a randomized controlled pilot trial to test the methods to be used in a larger randomized controlled trial. The Self-care in Heart Failure Index and Kansas City Cardiomyopathy Questionnaire surveys will be given at admission and four weeks after discharge. The Wake and Weigh tool is designed to help patients track weight in the hospital and following discharge. Feasibility endpoints will be summarized descriptively.
Recruiting
Has No Placebo
Cleveland Clinic Avon Hospital
Image of Emory University Hospital in Atlanta, United States.

EDEN System for Ventricular Arrhythmia

21 - 100
All Sexes
Atlanta, GA
Background: Heart surgeons use electrocardiogram (ECG) machines to record electrical signals from the heart during procedures. Normal ECG machines connect only to the skin. Special ECG machines connect directly to the heart; they are a safer option during procedures. Researchers want to test a new ECG machine called the EDEN system. Objective: To test the EDEN system in people having heart procedures. The new system will be used along with an approved special ECG machine. Eligibility: People aged 21 years or older who need to have a heart procedure. These procedures can include (1) electrophysiology mapping or ablation; and (2) conduction system pacing. Design: Researchers will review participants' medical records. No extra tests are needed. Participants will have their heart procedure as planned. The EDEN system will be linked to the special ECG used during the procedure. An extra electrode may be placed on the participant's body. Electrodes are small stickers attached to wires that go to the machine. The EDEN system will record and analyze electrical signals already being measured. It will not interfere with participants' care. No medical decisions well be made based on its data. No follow-up visits are needed for this study....
Waitlist Available
Has No Placebo
Emory University HospitalRobert J Lederman, M.D.
Image of Baystate Medical Center in Springfield, United States.

Consent Approaches for Heart Disease Rehabilitation

18+
All Sexes
Springfield, MA
Cardiac Rehabilitation is a lifestyle and exercise program for patients with heart disease. Cardiac Rehabilitation is strongly recommended in guidelines, but only 30% of eligible patients attend. New strategies are needed to help more patients attend cardiac rehabilitation. In this study, the investigators will see if using an $50 incentive, case management, text messages, and physical activity coaching combined into a single intervention will help more patients attend cardiac rehabilitation. In preparation for a larger trial, patients will also be randomly assigned to four different ways of seeking their permission to be in a research study. The investigators will see if these approaches affect how many people participate in the research project. The two main goals of this study is to understand: 1. If the consent approach type impacts participation rates in the research study 2. If the multi-component intervention (case management, financial incentives, text messages, and physical activity coaching) improves cardiac rehabilitation participation within 3 months.
Recruiting
Has No Placebo
Baystate Medical CenterQuinn R Pack, MD, MSc
Have you considered Lanoxicaps clinical trials? We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.Go to Trials
Image of University of Washington in Seattle, United States.

Behavioral Intervention for Cardiovascular Health in HIV/AIDS

18+
All Sexes
Seattle, WA
Heart failure (HF) is a growing health and economic burden around the globe, and it remains a leading cause of morbidity and mortality among the general population. HIV is recognized as an independent risk factor for HF, due to direct and indirect effects. Furthermore, people living with HIV (PLWH) now have an increased life expectancy due to the evolution and widespread use of antiretroviral therapy (ART), leading to a rising burden of cardiovascular disease (CVD) and HF among this population. Yet, the provision of appropriate guideline-recommended cardiovascular care is lower in PLWH compared to the general population, and there are no studies testing HF prevention interventions focused on PLWH. Current guidelines for HF management highlight the importance of a healthy lifestyle in preventing and treating HF. Among PLWH, tailored, innovative, and sustainable exercise delivery models are necessary to overcome barriers and increase physical activity (PA) adherence in this population. Building on the research team's prior mixed methods work and research expertise on exercise trials for PLWH, the investigators propose the Hybrid Exercise Intervention for Cardiovascular Health of People living with HIV (HEICA-HIV). HEICA-HIV is a novel multi-component 8-week intervention that will simultaneously deliver a supervised center-based (once a week) and a tailored home-based (twice a week) exercise intervention, together with exercise and cardiovascular health education. It will also involve behavioral coaching and mobile health support. The investigators evidence suggests that, by providing weekly exercise supervision together with a home-based prescription, the investigators can overcome difficulties associated with home-based programs (e.g., less intensive exercise training, less social support, and less face-to-face monitoring), and still observe the augmented health benefits obtained from supervised programs. Additionally, by requiring less time at the training center, this hybrid model can help with time restraints and transportation issues affecting marginalized populations, potentially increasing long-term exercise adherence in those who need it most. In this initial stage, HEICA-HIV will be focused on improving time in moderate-to-vigorous physical activity (MVPA). International guidelines recommend that every adult should engage in at least 150 minutes of MVPA per week in order to achieve optimal health benefits.
Waitlist Available
Has No Placebo
University of WashingtonVitor Oliveira, PhD
Image of Keck Hospital of the University of Southern California in Los Angeles, United States.

Mitral Valve Repair Procedures for Mitral Valve Prolapse

18+
All Sexes
Los Angeles, CA
The PRIMARY trial (NCT05051033), which compares mitral valve repair (MVr) to transcatheter-edge-to-edge-repair (TEER), offers a platform for conducting mechanistic studies to develop early insights into the pathophysiological processes by which mitral valve prolapse (MVP) can impact left ventricular (LV) myocardial structure and function, and, thereby, predispose to arrhythmias and sudden death. Such insights are key to identifying interventions to reduce the long-term sequelae of heart failure (HF) and arrhythmias, as well as delineate optimal therapeutic approaches for different patient sub-groups.
Recruiting
Has No Placebo
Keck Hospital of the University of Southern California (+15 Sites)Joanna Chikwe, MD
Have you considered Lanoxicaps clinical trials? We made a collection of clinical trials featuring Lanoxicaps, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security